UK-based clinical-stage biotechnology company TC BioPharm (Holdings) PLC (NASDAQ:TCBP) announced on Monday shareholder approval of a 25% stock dividend during its General Meeting.
The special dividend grants 0.25 American Depositary Shares (ADSs) for each ADS held on the record date of 2 January 2025, with delivery anticipated by 6 January 2025.
Trading in TC BioPharm's ADSs will pause at 17:00 hours on 2 January 2025, per Nasdaq requirements, resuming around 8 January 2025, to facilitate the dividend process. Nasdaq plans to adjust the opening price on 8 January to account for dilution from the dividend issuance.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government